Exploring the utility of a novel point-of-care whole blood thrombin generation assay following trauma: A pilot study

Michael J. Ferrara MS1 | Taleen A. MacArthur MD1 | Saulius Butenas PhD2 | Kenneth G. Mann PhD2 | Joseph M. Immermann CCRP1 | Grant M. Spears BS1 | Kent R. Bailey PhD1 | Rosemary A. Kozar MD, PhD3 | Stephanie F. Heller MD1 | Erica A. Loomis MD1 | Daniel Stephens MD1 | Myung S. Park MD, MS1

1Mayo Clinic, Rochester, MN, USA
2University of Vermont, Colchester, VT, USA
3Shock Trauma Center, University of Maryland School of Medicine, Baltimore, MD, USA

Correspondence
Myung S. Park, Division of Trauma, Critical Care and General Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. Email: Park.Myung@mayo.edu

Funding information
National Center for Research Resources, Grant/Award Number: 1 UL1 RR024150; National Heart, Lung, and Blood Institute, Grant/Award Number: R38HL150086; National Institute of General Medical Sciences, Grant/Award Number: R01 GM 126086-03; Trans-Agency Consortium of Trauma-Induced Coagulopathy, Grant/Award Number: TACTIC Grant and UM1 HL120877-06; National Center for Advancing Translational Sciences, Grant/Award Number: UL1 TR000135

Handling Editor: Pantep Angchaisuksiri.

Abstract
Introduction: Plasma thrombin generation kinetics as measured by the calibrated automated thrombogram (CAT) assay is a predictor of symptomatic venous thromboembolism after trauma. We hypothesized that data from a new prototype assay for measurement of thrombin generation kinetics in fresh whole blood (near patient testing of thrombin generation), will correlate with the standard CAT assay in the same patients, making it a potential tool in the future care of trauma patients.

Methods: Patients were enrolled from June 2018 to February 2020. Within 12 hours of injury, blood samples were collected simultaneously for both assays. Variables compared and correlated between assays were lag time, peak height, time to peak, and endogenous thrombin potential. Data are presented as median with interquartile range (IQR). Spearman and Pearson correlations were estimated and tested between both assays; a P value of <0.05 was considered to be significant.

Results: A total of 64 trauma patients had samples analyzed: injury severity score = 17 (IQR), 10-26, hospital length of stay = 7.5 (IQR), 2-18 days, age = 52 (IQR, 35-63) years, 71.9% male, and 42.2% of patients received a transfusion within 24 hours of injury. Thrombin generation parameters between plasma and whole blood were compared and found that all parameters of the two assays correlate in trauma patients.

Conclusion: In this pilot study, we have found that a novel point-of-care whole blood thrombin generation assay yields results with modest but statistically significant correlations to those of a standard plasma thrombin generation assay. This finding supports studying this device in a larger, adequately powered study.

KEYWORDS
calibrated, kinetics, plasma, thrombin, trauma, venous thromboembolism

Presentations: Abstract was presented as a poster at the AABB 2019 Annual Meeting, October 19-22, 2019 in San Antonio, Texas.

Mayo Clinic, Rochester, Rochester, MN (Primary Site of Research).

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2021 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).
**1 | INTRODUCTION**

Traumatic injury remains a leading cause of morbidity and mortality worldwide. In addition to physical and psychological trauma, these patients also face potential morbidity associated with trauma-induced coagulopathy (TIC).\(^1\)\(^-\)\(^4\) While effective resuscitation can treat the hemorrhagic effects of TIC, many of these patients suffer persistent hypercoagulability following trauma, even after hospital discharge. Prior work from Dr Park’s lab has shown that up to 40% of symptomatic venous thromboembolisms (VTEs), including deep vein thrombosis (DVT) and pulmonary embolism (PE), occur after hospital discharge, and that this risk remains elevated up to 3 months after trauma.\(^5\) Understanding an individual’s coagulation profile is essential in the care of trauma patients including initial resuscitation efforts, chemoprophylaxis administration, and postdischarge monitoring.

Laboratory tests that rapidly and accurately quantify TIC have the potential to augment care for trauma patients. Plasma-based assays, such as the calibrated automated thrombogram (CAT), have been developed that assess thrombin generation kinetics in real time.\(^6\)\(^,\)\(^7\) This assay is able to quantify an individual’s plasma thrombin generation profile in response to tissue factor (TF) and procoagulant phospholipid. Plasma-based CAT describes several parameters of thrombin generation that will be discussed here: lag time (LT), which is the time (minutes) to the start of thrombin generation; peak height (PH), which is the maximum thrombin concentration (nM) at a given time point during the assay; time to peak (tPeak), which is the time (minutes) to peak rate of thrombin generation; and endogenous thrombin potential (ETP), which is the total thrombin that can be generated during the assay (nM × minute). Prior studies have shown enhanced thrombin generation after trauma and that certain derangements in an individual’s plasma thrombin generation profile may be independent predictors of VTE after trauma.\(^8\)\(^,\)\(^9\)\(^,\)\(^10\) Unfortunately, plasma thrombin generation assays are not amenable to point-of-care (POC) use because they are typically run in batches of several patient samples at a time. Additionally, the absence of platelets and other cellular components in a plasma-based assay potentially limits the approximation of physiologic conditions.

A novel method of measuring thrombin generation kinetics in fresh whole blood has been developed that allows for near patient testing of thrombin generation (NPT-TG). This POC assay has the potential to provide information about an individual’s coagulation profile that could be applied at the bedside. Additionally, the testing of whole blood rather than plasma includes platelets and other cellular components involved in clot formation. The novel whole blood assay measures thrombin generation kinetics in a manner similar to the standard plasma-based assay. A TF agonist initiates a clotting reaction in the presence of a fluorogenic substrate, which changes as thrombin is generated. The results are standardized against a calibrator of known activity, and a curve is produced showing thrombin activity over time.

In this pilot study, our main objective was to compare thrombin generation parameters from this novel whole blood assay with those of the well-established plasma-based assay. We hypothesized that thrombin generation kinetics measured in whole blood will correlate with plasma thrombin generation parameters. We anticipate that these correlations will likely be modest due to the presence of platelets and cellular components in whole blood, with these two assays offering complementary views of an individual’s coagulation profile.

**2 | METHODS**

**2.1 | Study design, setting, and population**

This study was approved by the Mayo Clinic Institutional Review Board and conducted using a waiver of informed consent. Adult patients presenting to the Mayo Clinic Emergency Department as trauma activations, from June 2018 through February 2020 were considered for study inclusion. Exclusion criteria included age <18 years, ongoing systemic anticoagulation at presentation (eg, heparin, warfarin, or novel oral anticoagulants) other than antiplelet agents, known preexisting coagulopathy, cirrhosis, active malignancy, sepsis, renal failure requiring dialysis, burn injuries, or recent major surgery or another significant trauma in the past year, as well as pregnant women or prisoners. Trauma patients or their legal authorized representative (LAR) gave consent for this study after the collection of one or more blood samples. If the patient or LAR could not be consented for study participation or declined consent, the sample was destroyed and the patient was excluded. The time of injury (TOI) was determined by theprehospital medical providers based on information at the injury scene. We collected demographic and clinical characteristics for each patient from the electronic medical record.

**2.2 | Blood sample collection**

Blood samples were collected from both trauma patients and healthy volunteers, who were recruited as outpatients specifically for this study. Healthy volunteers provided full written informed consent before any sample collection. Two separate samples were obtained
from each subject: one for the whole blood thrombin generation assay and one for plasma thrombin generation, as described below. Blood was collected simultaneously for both assays through venipuncture or from indwelling catheters. Samples were collected upon patient arrival, up to 12 hours from the TOI for the trauma patients.

2.3 | Platelet-poor plasma collection

A total of 4.5 mL of whole blood was collected by venipuncture or via existing indwelling catheters into citrated Vacutainer tubes (0.105 M of buffered sodium citrate, 3.2%; Becton Dickinson, East Rutherford, NJ, USA). Within 20 minutes of collection, blood was processed to platelet-free plasma by double centrifugation (3000 g, 15 minutes), as recommended by the International Society on Thrombosis and Haemostasis vascular biology Scientific and Standardization Committee Collaborative Workshop,11 and stored in multiple aliquots at −80°C until subsequent batch analysis.

2.4 | Whole blood collection

Whole blood was collected in 4-mL evacuated tubes containing both sodium citrate (3.2%) and corn trypsin inhibitor (CTI; 100 µg/mL; Hematologic Technologies, Essex Junction, VT, USA). The whole blood thrombin generation assay was run within 30 minutes of the blood draw. If the whole blood assay was unable to be run within 30 minutes of the blood draw, the sample was discarded.

2.5 | Calibrated automated thrombogram analyses

Thrombin generation kinetics were measured with the CAT assay (Thrombinoscope BV, Maastricht, Netherlands), utilizing a Fluoroskan Ascent plate reader (390 nm excitation, 460 nm emission, Thermo Electron Corp, Vantaa, Finland), as previously described by Hemker et al.6,7 Assays of trauma patient samples were performed in triplicate. CTI was added to 800 µL of plasma for a final concentration of 50 µg/mL CTI before sample analysis. Thrombin generation was initiated using two different reagents: addition of 20 µL of platelet-poor plasma (5 nM of TF and 4 µM phospholipids, Diagnostica Stago Inc, Parsippany, NJ, USA) reagent. Then, 80 µL of citrated plasma was added to each well of U-bottom 96-well microtiter plates (Nunc; Thermo Fisher Scientific, Waltham, MA, USA) using a single-channel pipette. After an incubation period (15 minutes at 37°C), 20 µL of warmed FluCa reagent (Fluca kit, Diagnostica Stago Inc), which contains the fluorogenic substrate and calcium chloride (CaCl$_2$) was added to each well via an automated dispenser. Thrombin generation curves were recorded continuously for 90 minutes at a rate of three readings per minute. Separate wells containing the thrombin calibrator, which corrects for inner filter effects and quenching variation among individual plasmas were also measured in parallel. A dedicated software program, Thrombinscope (Thrombinscope BV) was used to calculate thrombin activity over time. The parameters derived were LT, PH, ttPeak, and ETP.

2.6 | Near patient testing of thrombin generation

Thrombin generation kinetics in whole blood was measured using the NPT-TG, a prototype machine designed by Stago (Diagnostica Stago, Asnières-sur-Seine, France) specifically for this purpose. This device is not US Food and Drug Administration approved but is currently under investigation at three trauma centers. The NPT-TG assay operates on the same principle as plasma-based CAT, measuring the change of a thrombin-specific fluorogenic substrate over time, and comparing this measurement against a calibrator with a known value of thrombin activity. Two activating solutions are prepared in 0.5% bovine serum albumin (BSA). One is a control without TF. The other is a solution of 26-pM relipidated human TF in 0.5% BSA buffer with CaCl$_2$ added as an agonist to initiate clotting reaction, with the final concentrations of 6.5 pMTF, 16.7 mM CaCl$_2$, and CTI 50 µg/mL. The fluorogenic substrate (1.67 mM) is added. The test condition is run in two individual channels, alongside a third control channel with no TF. Thrombin generation curves are recorded continuously at a rate of three readings per minute for about 75 minutes. These channels are each measured in triplicate and the results averaged. The results are measured using software provided by Stago (Diagnostica Stago). The rate of thrombin generation is measured over time and produces a curve analogous to that generated by the plasma thrombin generation assay, allowing comparison of LT, PH, ttPeak, and ETP. Per Stago’s recommendation, control tests are performed weekly using a control reagent provided by Stago (NPT-TG Coag Control) in lieu of whole blood. Coefficient of variation (CV, %) ranges for the individual whole blood assays included in this series (n = 64) as well as control tests (n = 44) were calculated and are reported below.

2.7 | Statistical analyses

Categorical variables were summarized as n (%). Continuous variables were summarized as median with interquartile ranges (IQRs) and compared using the Kruskal-Wallis test. Pearson correlations and Spearman rank correlations were estimated and tested for significance between plasma and the corresponding whole blood variables. The assessment of association was based on the more robust Spearman correlation, while Pearson correlations were estimated primarily for descriptive purposes. A P value of <0.05 was considered to be statistically significant. Trauma patients were also analyzed with and without a subgroup of patients taking antiplatelet medications, and both Pearson and Spearman rank correlations were estimated between the plasma and whole blood parameters for each of those groups. All analysis was performed using SAS, version 9.4 (SAS Institute, Cary, NC, USA).
EIGHTY-NINE patients were screened for participation, 5 patients met exclusion criteria, 17 patients declined consent, and 3 patients were excluded due to technical errors with the whole blood thrombin generation assay (one instance of blood collected in the wrong tube, one error preparing reagents, and one mechanical error with machine after the assay had begun). The remaining cohort of 64 trauma patients had a median age of 52 (IQR, 35-63), median injury severity score of 17 (10-24), 71.9% were male, and 96.9% had blunt mechanism of injury. As described in Table 1, 27 (42.2%) required blood product transfusion, and 10 (15.6%) required massive transfusion defined as >3 units of red blood cells within any 60-minute period.\(^2\) Of the patients who received blood product transfusion at any point in their treatment course, 18 of 27 (66.6%) were transfused before the blood draw for this study. Six patients (9.4%) developed VTE during hospitalization. One sample from a patient with VTE clotted in a sodium citrate tube before it could be processed, so plasma thrombin generation data are available for 63 of the 64 patients, while whole blood thrombin generation data are available for all 64 trauma patients.

Trauma patients were compared with 13 healthy volunteers, who had a median age of 35 (25-39) and were 61.5% female (Table 1). All of the female controls were premenopausal and 3 of 8 (37.5%) were on the Nexplanon (etongestrel 68 mg) hormonal contraceptive implant at the time of sample collection. As described in Table 1, 27 (42.2%) required blood product transfusion, and 10 (15.6%) required massive transfusion defined as >3 units of red blood cells within any 60-minute period.\(^1\)\(^2\) Of the patients who received blood product transfusion at any point in their treatment course, 18 of 27 (66.6%) were transfused before the blood draw for this study. Six patients (9.4%) developed VTE during hospitalization. One sample from a patient with VTE clotted in a sodium citrate tube before it could be processed, so plasma thrombin generation data are available for 63 of the 64 patients, while whole blood thrombin generation data are available for all 64 trauma patients.

Trauma patients were compared with 13 healthy volunteers, who had a median age of 35 (25-39) and were 61.5% female (Table 1). All of the female controls were premenopausal and 3 of 8 (37.5%) were on the Nexplanon (etongestrel 68 mg) hormonal contraceptive implant at the time of sample collection. As described in Table 1, 27 (42.2%) required blood product transfusion, and 10 (15.6%) required massive transfusion defined as >3 units of red blood cells within any 60-minute period.\(^1\)\(^2\) Of the patients who received blood product transfusion at any point in their treatment course, 18 of 27 (66.6%) were transfused before the blood draw for this study. Six patients (9.4%) developed VTE during hospitalization. One sample from a patient with VTE clotted in a sodium citrate tube before it could be processed, so plasma thrombin generation data are available for 63 of the 64 patients, while whole blood thrombin generation data are available for all 64 trauma patients.

When reviewed separately from the rest of the cohort, there were no statistically significant correlations between the plasma and whole blood thrombin generation parameters for these 13 patients. However, when the remaining trauma patients who are not on any antplatelet medications in both the plasma (265.8 [IQR, 218.8-309.3] vs 229.1 [IQR, 203.4-241.7]; \(P = .02\)) and whole blood assays (111.2 [IQR, 100.9-128.7] vs 98.0 [IQR, 81.6-110.9]; \(P = .05\)). Trauma patients on antplatelet medications also had a significantly decreased ETP (nM × minute) as compared to those not on those medications in both the plasma (111.2 [IQR, 100.9-128.7] vs 98.0 [IQR, 81.6-110.9]; \(P = .05\)).

For each of the whole blood patient and control assays (NPT-TG Coag Control), CV was calculated among the three thrombin generation curves. For the whole blood assays, CV range for LT was 0.93%-7.37%, CV range for ttPeak was 0.60%-7.48%, CV range for PH was 0.12%-15.8% (3/64 samples had a CV > 10% for PH), and CV range for ETP was 0.93%-19.2% (21/61 samples a CV > 10% for ETP). For the control assays, CV range for LT was 1.69%-14.85% (1/44 tests with CV > 6%), CV range for ttPeak was 1.05%-6.72%, CV range for
In this pilot study, we sought to compare and correlate thrombin generation parameters from the well-established plasma thrombin generation assay with a novel POC prototype assay for whole blood thrombin generation. We found a modest but statistically significant correlation between the plasma and whole blood assays for all thrombin generation parameters in trauma patients.

The raw values for each thrombin generation parameter from these two assays differ, as anticipated, given that they employ different tools, methodologies, and sample types (whole blood vs plasma) to measure the same pathway. Some of the differences in these values may be explained by the presence of platelets and cellular components.

**TABLE 2** Comparison of individual plasma and whole blood thrombin generation parameters for trauma patients and healthy volunteers expressed as median (interquartile range)

| Test parameter                  | Trauma patients (n = 64) | Healthy volunteers (n = 13) | P value |
|---------------------------------|-------------------------|-----------------------------|---------|
| Lag time (minutes)              |                         |                             |         |
| Plasma                          | 3.6 (3.2-4.7)           | 3.6 (3.2-3.6)               | .36     |
| Whole blood                     | 4.3 (3.5-4.8)           | 3.2 (2.9-3.5)               | <.01    |
| Peak height (nM)                |                         |                             |         |
| Plasma                          | 248.9 (214.1-302.0)     | 164.8 (130.4-211.9)         | <.01    |
| Whole blood                     | 109.1 (97.4-128.2)      | 110.3 (101.3-125.4)         | .69     |
| Time to peak, min               |                         |                             |         |
| Plasma                          | 6.4 (5.7-7.7)           | 7.5 (7.0-8.2)               | .02     |
| Whole blood                     | 7.3 (6.3-8.2)           | 5.6 (5.3-5.8)               | <.01    |
| Endogenous thrombin potential, nM × min |  |                             |         |
| Plasma                          | 1,358 (1168-1521)       | 1206 (1129-1472)            | .29     |
| Whole blood                     | 784.0 (685.0-892.0)     | 566.0 (505.0-743.0)         | <.01    |

*Plasma thrombin generation results are missing for one trauma patient. Bold values indicate a P-value of < .05 and are considered significant.

**TABLE 3** Spearman and Pearson correlations between plasma and whole blood thrombin generation parameters in all trauma patients (n = 63) presented in the top half of the table

| Thrombin generation parameters (all trauma patients) | Pearson correlation coefficient | P value | Spearman correlation coefficient | P value |
|-----------------------------------------------------|--------------------------------|---------|---------------------------------|---------|
| Lag time, min                                       | 0.55                           | <.01    | 0.40                            | <.01    |
| Peak height, nM                                      | 0.44                           | <.01    | 0.466                           | <.01    |
| Time to peak, min                                   | 0.555                          | <.01    | 0.356                           | <.01    |
| Endogenous thrombin potential, nM × min             | 0.095                          | .46     | 0.54                            | <.01    |

| Thrombin generation parameters (patients not on antplatelet) | Pearson correlation coefficient | P value | Spearman correlation coefficient | P value |
|-------------------------------------------------------------|--------------------------------|---------|---------------------------------|---------|
| Lag time, min                                               | 0.65                           | <.01    | 0.47                            | <.01    |
| Peak height, nM                                             | 0.57                           | <.01    | 0.53                            | <.01    |
| Time to peak, min                                           | 0.67                           | <.01    | 0.42                            | <.01    |
| Endogenous thrombin potential, nM × min                     | 0.22                           | .13     | 0.68                            | <.01    |

Note: Spearman and Pearson correlations between plasma and whole blood thrombin generation parameters for the trauma patients who are not on any antplatelet agents (n = 50) presented in the bottom half of the table.

Bold values indicate a P-value of < .05 and are considered significant.

PH was 1.19%-108.24% (7/44 tests with CV > 7%), and CV range for ETP was 1.30%-58.93% (8/44 tests with CV > 10%, and 2 of those with CV > 15%).

**4 | DISCUSSION**

In this pilot study, we sought to compare and correlate thrombin generation parameters from the well-established plasma thrombin generation assay with a novel POC prototype assay for whole blood thrombin generation. We found a modest but statistically significant correlation between the plasma and whole blood assays for all thrombin generation parameters in trauma patients.
in the whole blood assay as compared to plasma. Platelets play an important role in controlling the thrombin burst that results in fibrin clot formation. Additionally, red blood cells have been shown in vitro to augment prothrombin activation and bolster thrombin release through the meizothrombin pathway. Differences in the levels of thrombin generation between whole blood and plasma due to the presence of differing cellular components was also hypothesized and demonstrated by Coleman et al in another study of this novel whole blood thrombin generation assay, and our results are consistent with this. These differences in part explain why the correlations between the two assays are modest, as these assays are complementary; showing different aspects of an individual’s clotting profile.

When the trauma cohort was analyzed with the 13 patients who were taking antiplatelet agents removed, correlations between the plasma and whole blood thrombin generation assays increased (Table 3). This emphasizes the important role of platelets in thrombin generation that is captured in the whole blood assay. The important role of platelets is also supported by the fact that the patients taking antiplatelet agents had lower PH than the rest of the trauma patients. This indicates that these patients may not make as much thrombin, likely due to thrombin generation being reduced by those medications.

Prior work from our lab showed that plasma $tt_{Peak}$ is an independent predictor of VTE development up to 92 days after trauma. As shown in Figure 1, among the 5 VTE patients who have thrombin generation data available, the majority appear to have shorter LT and $tt_{Peak}$ than trauma patients who did not develop VTE. This should continue to be examined in a larger cohort to evaluate if the whole blood thrombin generation assay has a similar predictive value for VTE after trauma to the plasma thrombin generation assay.

Interestingly, the healthy volunteers in this study showed more accelerated thrombin generation than trauma patients using the whole blood assay. In this small pilot study, we had only 13 healthy volunteers, the majority of which were premenopausal females, while the trauma cohort was predominantly middle-aged males. This is because enrollment of healthy controls had to be paused early due to the coronavirus disease 2019 pandemic. Though data are limited,
prior studies have shown that reproductive-age females have more accelerated thrombin generation than males and that this can be influenced both by menstrual cycle stage and use of hormonal contraceptives. Additionally, prior studies have shown an acceleration of thrombin generation with age in healthy adults using the plasma CAT assay. The impact of age on the whole blood thrombin generation assay has not yet been established, and it may be that varying levels of cellular components and hormones with age may impact this assay differently.

This study has several additional limitations. First, given that this is a pilot study with a small number of patients, selection bias is certainly a concern. Additionally, because blood samples were collected up to 12 hours from the time of injury, 18 of the 64 trauma patients received some blood product transfusion before sample collection. Blood product transfusion can influence thrombin generation by introducing exogenous clotting factors, thus altering an individual’s thrombin generation profile. Additionally, prior studies have isolated large numbers of procoagulant microparticles from stored blood and have demonstrated the ability of microparticles to generate thrombin through a factor Xla-mediated pathway in the absence of TF, which could also impact thrombin generation results in patients who received blood product transfusion before sample collection. Additionally, as described in the methods section, samples for the whole blood assay were collected in 3.2% citrated tubes containing 100 µg/mL CTI, while the samples from the plasma-based assay were collected in 3.2% citrated tubes that did not contain CTI. Because of this difference in collection technique, the samples used in the plasma assay could have had the intrinsic pathway stimulated before addition of CTI to plasma at the time of the assay. This may be one reason to explain why the correlations between the two assays were not more robust.

We observed that when patients taking antiplatelet medications were removed from the trauma cohort, correlation coefficients improved between the plasma and whole blood thrombin generation assays. These results should be interpreted cautiously as these patients were heterogeneous in terms of what medications and dosages they were taking, and we do not know to what extent they were taking these medications as prescribed. As such, these results may reflect varying degrees of platelet inhibition.

5 | CONCLUSION

The novel POC prototype whole blood thrombin generation assay has potential clinical utility in the care of trauma patients, given that it can be run near the patient as opposed to the standard plasma-based thrombin generation assay, which is not amenable to bedside use. Our pilot study shows that in trauma patients, the plasma and whole blood thrombin generation assays significantly correlate. A larger cohort is needed to assess if the novel whole blood thrombin generation assay is comparable to the plasma-based assay in predicting VTE and hemorrhagic complications, as we have shown previously in our laboratory.

ACKNOWLEDGMENTS

Funding Sources: This project was supported by R38HL150086 Stimulating Access to Research in Residency (TAM) from the National Heart, Lung, and Blood Institute, R01 GM 126086-03 (MSP) from the National Institute of General Medical Sciences, 1 UL1 RR024150 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), the NIH Roadmap for Medical Research and by Grant Number UL1 TR000135 from the National Center for Advancing Translational Sciences. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or NCRR.

RELATIONSHIP DISCLOSURE

KGM holds consulting positions for Stago Diagnostica and Baxalta/Shire; he owns stock with Novo Nordisk, Catalyst, Baxter, Allergen, and Alnylam, and is the former owner of Haematologic Technologies. All other authors, including MJF, TM, GS, JI, KRB, RK, SB, SH, EL, DS, and MSP have no relevant conflicts of interests or disclosures.

AUTHOR CONTRIBUTIONS

MJF: study design, data collection and analysis, critical writing, and revising of manuscript; TAM: data analysis and interpretation, critical writing, and revising of manuscript; SB: study design and critical revising of manuscript; KGM: study design and critical revising of manuscript; GMS: critical revising of manuscript and data analysis and interpretation; KRB: critical revising of manuscript, and data analysis and interpretation; RAK: study design and critical revising of manuscript; SFH: critical revising of manuscript; EAL: data interpretation and critical revising of manuscript; DS: study design, data interpretation, and critical revising of manuscript; MSP: study design, data collection, data analysis and interpretation, critical writing, and revising of manuscript.

TWITTER

Taleen A. MacArthur @TaleenMacarthur

REFERENCES

1. Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma. 2003;54:1127–30.
2. Davenport RA, Brohi K. Cause of trauma-induced coagulopathy. Curr Opin Anaesthesiol. 2016;29:212–9.
3. Chang R, Cardenas JC, Wade CE, Holcomb JB. Advances in the understanding of trauma-induced coagulopathy. Blood. 2016;128:1043–9.
4. Cohen MJ, Christie SA. Coagulopathy of trauma. Crit Care Clin. 2017;33:101–18.
5. Park MS, Perkins SE, Spears GM, Ashrani AA, Leibson CL, Boos CM, et al. Risk factors for venous thromboembolism after acute trauma: a case-cohort study. Thromb Res. 2016;144:40–5.
6. Hemker HC. Recollections on thrombin generation. J Thromb Haemost. 2008;6:219–26.
7. Hemker HC, Al Dieri R, De Smedt E, Beguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost. 2006;96:553–61.
8. Park MS, Xue A, Spears GM, Halling TM, Ferrara MJ, Kuntz MM, et al. Thrombin generation and procoagulant microparticle profiles
after acute trauma: a prospective cohort study. J Trauma Acute Care Surg. 2015;79:726–31.
9. Park MS, Owen BA, Ballinger BA, Sarr MG, Schiller HJ, Jenkins DH, et al. Quantification of hypercoagulable state after blunt trauma: microparticle and thrombin generation are increased relative to injury severity while standard markers are not. Surgery. 2012;151:831–6.
10. Park MS, Spears GM, Bailey KR, Xue A, Ferrara MJ, Headlee A, et al. Thrombin generation profiles as predictors of symptomatic venous thromboembolism after trauma: a prospective cohort study. J Trauma Acute Care Surg. 2017;83:381–7.
11. Lacroix R, Judicone C, Mooberry M. Standardization of preanalytical variables in plasma microparticle determination: results of the International Society on Thrombosis and haemostasis SSC Collaborative workshop. J Thromb Haemost. 2013;11:1190–3.
12. Savage SA, Sumislawski JJ, Zarzaur BL, Dutton WP, Croce MA, Fabian TC. The new metric to define large-volume hemorrhage: results of a prospective study of the critical administration threshold. J Trauma Acute Care Surg. 2015;78:224–9.
13. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol. 2002;22:1381–9.
14. Whelihan MF, Zachary V, Orfeo T, Mann KG. Prothrombin activation in blood coagulation: the erythrocyte contribution to thrombin generation. Blood. 2012;120:3837–45.
15. Whelihan MF, Mann KG. The role of the red cell membrane in thrombin generation. Thromb Res. 2013;131:377–82.
16. Coleman JR, Moore EE, Samuels JM, Ryon JJ, Nelson JT, Olson A, et al. Whole blood thrombin generation is distinct from plasma thrombin generation. Surgery. 2019;166:1122–7.
17. Chaireti R, Gustafsson KM, Bystrom B, Bremme K, Lindahl TL. Endogenous thrombin potential is higher during the luteal phase than during the follicular phase of a normal menstrual cycle. Hum Reprod. 2013;29:1846–52.
18. Marchi R, Marcos L, Paradisi I. Comparison by sex between thrombin generation and fibrin network characteristics in a healthy population. Clin Chim Acta. 2015;441:86–9.
19. Rotteveel RC, Roozendaal KJ, Eijssens L, Hemker HC. The influence of oral contraceptives on the time-integral of thrombin generation (thrombin potential). Thromb Haemost. 1993;70:959–62.
20. Calzavarini S, Brocard J, Quarroz C, Maire L, Nutzi R, Jankovic J, et al. Thrombin generation measurement using the ST Genesia Thrombin Generation System in a cohort of healthy adults: normal values and variability. Res Pract Thromb Haemost. 2019;3:758–68.
21. Haidl H, Cimenti C, Leschnik B, Zach D, Muntean W. Age-dependency of thrombin generation measured by means of calibrated automated thromboagrapy (CAT). Thromb Haemost. 2006;95:772–5.
22. Dhillon SK, Houck ML, Jenkins DH, Rosedahl JK, Harmsen WS, Halling TM, et al. Transfusion of stored red blood cells in trauma patients is not associated with increased procoagulant microparticles. J Trauma Acute Care Surg. 2014;77:674–8.
23. Rubin O, Delobel J, Prudent M, Lion N, Kohl K, Tucker EI, et al. Red blood cell–derived microparticles isolated from blood units initiate and propagate thrombin generation. Transfusion. 2013;53:1744–54.
24. Gao Y, Lv L, Liu S, Ma G, Su Y. Elevated levels of thrombin-generating microparticles in stored red blood cells. Vox Sang. 2013;105:11–7.
25. MacArthur T, Spears GM, Kozar RA, Dong JF, Auton M, Jenkins DH, et al. Thrombin generation kinetics are predictive of rapid transfusion in trauma patients meeting critical administration threshold. Shock. 2020. [Epub ahead of print].

How to cite this article: Ferrara MJ, MacArthur TA, Butenas S, et al. Exploring the utility of a novel point-of-care whole blood thrombin generation assay following trauma: A pilot study. Res Pract Thromb Haemost. 2021;5:395–402. https://doi.org/10.1002/rth2.12483